Business
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
LOS ANGELES, January 07, 2026--Puma Biotechnology reported inducement awards granted to December 2025 new hires, in accordance with Nasdaq Listing Rule 5635(c)(4).
About this update from Puma Biotechnology Inc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2400,"height":800,"url":"https://media.zenfs.com/en/business-wire.com/7a023788857d02d807c12786e825ba46"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/wZCuBOLuokp.wqyVswLR2A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMyMDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/7a023788857d02d807c12786e825ba46","width":960,"height":320},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/2O_wymZSRLgN_Ie28E1Otg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04MDA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/7a023788857d02d807c12786e825ba46","width":1200,"height":400}},"lazy":false},{"type":"text","content":"LOS ANGELES, January 07, 2026--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on January 6, 2026, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering 10,500 shares of Puma common stock to three new non-executive employees.","length":352,"tagName":"p"},{"type":"text","content":"The awards were granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying the award vesting on the first anniversary of the award’s vesting commencement date, January 1, 2026, and one-sixth of the shares underlying the award vesting on each six-month anniversary of the vesting commencement date thereafter, subject to continued service. The awards were granted as an inducement material to the new employees entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).","length":720,"tagName":"p"},{"type":"text","content":"About Puma Biotechnology","length":24,"tagName":"p"},{"type":"text","content":"Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral) in 2011. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuva...